Loading...
•
Jun 30, 2021
Amneal Q2 2021 Earnings Report
Amneal's Q2 2021 financial results were announced, featuring net revenue of $535 million and GAAP net income of $15 million.
Key Takeaways
Amneal Pharmaceuticals reported a strong second quarter in 2021, with net revenue reaching $535 million, a 15% increase compared to the second quarter of 2020. The company's GAAP net income was $15 million, a significant improvement from the net loss of $12 million in the same period last year. Adjusted EBITDA was $151 million, up 50% year-over-year, and adjusted diluted EPS was $0.25, a 92% increase.
Net revenue for Q2 2021 was $535 million, a 15% increase year-over-year.
GAAP net income for Q2 2021 was $15 million, compared to a net loss of $12 million in Q2 2020.
Adjusted EBITDA for Q2 2021 was $151 million, a 50% increase year-over-year.
Adjusted diluted EPS for Q2 2021 was $0.25, a 92% increase year-over-year.
Amneal
Amneal
Amneal Revenue by Segment
Revenue by Segment
Affordable Medicines Revenue
CapyFin.comSpecialty Revenue
CapyFin.comAvKARE Revenue
CapyFin.com Forward Guidance
Amneal is maintaining its previously provided full year 2021 financial guidance.
Positive Outlook
- Net revenue: $2.1 billion - $2.2 billion
- Adjusted EBITDA: $500 million - $540 million
- Adjusted diluted EPS: $0.70 - $0.85
- Operating cash flow: $220 million - $250 million
- Capital expenditures: $60 million - $70 million
Revenue & Expenses
Visualization of income flow from segment revenue to net income